3 results
Approved WMOCompleted
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Approved WMOCompleted
Compare if once daily laba/lama treatment with two different dosages shows the same or better result on the 24 hr lungfunction than twice daily treatment of two different dosages with ICS/laba treatment. .
Approved WMORecruiting
The VAT project is set out to prove that this approach is superior and that the Quality of Life of children with amblyopia might be significantly improved in comparison to occlusion therapy.